Loading organizations...
Key people at Goddess Gaia Ventures.
Goddess Gaia Ventures is a London-based venture capital firm that invests in pre-Series A startups focused on women’s health, wellness, femtech, and sports. Operating as Europe's first dedicated women-centric healthcare fund, the organization provides capital to female-led healthtech companies addressing systemic gaps in the medical industry. The firm actively supports its portfolio companies by helping them scale operations from European markets into the United States healthcare ecosystem. Goddess Gaia Ventures is currently targeting a £100 million debut fund, having already completed 11 initial investments, while its leadership team has historically invested in over 150 companies to achieve a 16x multiple on invested capital. The firm's executive leadership and investment committee include recognizable industry figures such as James Benedict, Alexandra Lemacon, and Maria Molland. Goddess Gaia Ventures was established in 2021 by founding partner Priya Oberoi.
# Goddess Gaia Ventures: Europe's Dedicated Women's Healthcare Investment Platform
Goddess Gaia Ventures (GGV) is Europe's first and only dedicated venture capital fund focused exclusively on women's healthcare and performance innovation.[1][2] The firm's mission centers on backing pre-Series A technology companies that address healthcare solutions affecting women disproportionately or uniquely, filling a critical gap where women's health remains an outlier in most mainstream VC portfolios.[1]
The fund's investment philosophy prioritizes both financial returns and measurable impact, with the team leveraging deep healthcare expertise and an extensive network to help portfolio companies scale from Europe to the US market—where founders gain access to larger market opportunities, additional funding, and the world's largest technology ecosystem.[1] GGV operates as a growth seed capital provider, supporting founders (both female and male) solving women's health challenges across multiple therapeutic areas and wellness domains.
Founded in 2021, Goddess Gaia Ventures emerged from London as a female-founded venture capital firm with leadership rooted in healthcare and investment expertise.[4] The firm's leadership team brings formidable credentials: Chairman James Benedict has over 25 years of experience in private equity, venture capital, and family office investing, and previously co-founded two pioneering platforms advancing race and gender equity in private markets.[1] Alexandra Lemacon, another key leader, served as head of strategy and innovation at BUPA, bringing deep operational healthcare knowledge.[1]
The firm was incorporated on 15 October 2020 and operates from 35 Berkeley Square in Mayfair, London.[3] Its founding reflected a deliberate recognition that women's healthcare—despite representing a massive market opportunity—remained significantly underfunded relative to its potential impact and commercial viability.
GGV's current portfolio consists of 11 women's healthcare startups across the UK and Europe, including:[1]
Goddess Gaia Ventures operates at the intersection of two powerful trends: the growing recognition of women's health as a massive, underserved market and the rise of impact-driven venture capital that aligns financial returns with social outcomes.
The firm capitalizes on a structural market inefficiency—women's healthcare has historically received disproportionately low venture funding despite representing roughly half the global population and distinct healthcare needs. By specializing exclusively in this space, GGV positions itself as the go-to partner for founders solving these problems while simultaneously building a defensible competitive advantage through network effects, regulatory expertise, and deal flow concentration.
The firm's emphasis on helping European companies access US markets also reflects broader ecosystem dynamics: Europe has strong healthcare innovation talent but often lacks the scale and capital density of US markets. GGV bridges this gap, effectively creating a transatlantic pipeline that strengthens both ecosystems.
Goddess Gaia Ventures is well-positioned to become the category-defining investor in women's healthcare innovation, particularly as regulatory tailwinds (FDA focus on women's health representation in clinical trials) and market forces (aging populations, preventive care emphasis) accelerate demand for specialized solutions.
The firm's Fund II is currently in fundraising, signaling confidence in the market opportunity and the team's ability to deploy capital effectively.[2] As women's health gains mainstream attention—driven by both commercial opportunity and policy momentum—GGV's early specialization and operational expertise will likely translate into outsized returns and meaningful impact.
The key to sustained success will be maintaining the balance between financial discipline and mission alignment while scaling the portfolio without diluting the specialized expertise that makes the firm distinctive. If GGV continues executing on its US expansion strategy and building portfolio companies into category leaders, it could establish itself as the premier women's healthcare venture platform globally.
Key people at Goddess Gaia Ventures.
